VC Phf6 + JAK3M511I T-ALL mice were treated with placebo, single tofacitinib, single idasanutlin, or combined tofacitinib + idasanutlin (To + Id) (Fig. 7A). Here, ID1 is linked to acute lymphoblastic leukemia.